Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAD: Dasatinib for Treatment-free Remission in CML
NCT02268370Phase 2Unknown
- Sponsor
- University Health Network
- Start
- Oct 2014
- Primary completion
- Oct 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by University Health Network. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02268370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268370.